What should I avoid while taking Asenapine 5.7mg/24hours transdermal patches?

Take separate from meals. Do not have food or water for 10 minutes after administration. (Source: DrugBank, licensed under CC BY-NC 4.0)

Do I need a prescription for Asenapine 5.7mg/24hours transdermal patches?

Asenapine 5.7mg/24hours transdermal patches is classified as a Valid as a prescribable product in the UK. However, always consult a pharmacist or doctor before use. (Source: NHS dm+d)

What are the brand names for Asenapine 5.7mg/24hours transdermal patches?

Asenapine 5.7mg/24hours transdermal patches is the generic name. It is available under brand names including: Asenapine 5.7mg/24hours transdermal patches. (Source: NHS dm+d — Actual Medicinal Products)

Asenapine 5.7mg/24hours transdermal patches

Patch

5.7mg/24hour

Other

Active ingredients:

Asenapine

Check interactions for Asenapine

No active safety alerts

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Suspected adverse reactions reported for Asenapine

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

View EudraVigilance report

Suspected adverse reactions reported for Asenapine

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

1 branded products available

1 productsShow details

1 products

Possibly available on the UK marketRestricted supplyDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Asenapine on the MHRA register

Asenapine 5.7mg/24hours transdermal patches

Imported

None

Imported

Source: NHS dm+dOGL 3.0

Updated about 1 month ago(1 Mar 2026)

Clinical guidelines and formulary information

British National Formulary

Asenapine

BNF

Drug monograph — bnf.nice.org.uk

Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.

NICE clinical guidance(1)

Bipolar disorder: assessment and management (CG185)

CG185

Clinical guideline

Updated Sept 2025

Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.

Check stock at pharmacies and supply information

Show details

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & product information

Official product databases and supply status monitoring

Shortages info

NHS Specialist Pharmacy Service (SPS)

emc product search

Discontinuations & alternatives for Asenapine

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.

Codes for healthcare professionals and prescribing systems

Show details

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

45707511000001107

dm+d ID

45707511000001107

VTM (Virtual Therapeutic Moiety)

774652006

VMP (Virtual Medicinal Product)

45707511000001107

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA).

Active and completed clinical studies from ClinicalTrials.gov

Show details

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

38 found

Half-life

24 hours

Mechanism

Asenapine is an atypical antipsychotic multireceptor neuroleptic drug which show…

Food interactions

1 warning

Human targets

20 targets

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

5 mg

Cmax, single 5 mg dose = 4 ng/mL (within 1 hour);
Bioavailability, sublingual administration = 35%;
Bioavailability, oral administration (swallowed)…

Half-life

24 hours

24 hours (range of 13.4 - 39.2 hours)

Protein binding

95%

95% protein bound

Volume of distribution

20-25 L/kg

20-25 L/kg

Metabolism

Asenapine is oxidized via CYP1A2 and undergoes direct glucuronidation via UGT1A4. Oxidation via CYP1A2 is asenapine's primary mode of metabolism.

Elimination

50%

Urine (50%) and feces (50%)

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Investigational

Small molecule

About this compound

Developed by Schering-Plough after its merger with Organon International, asenapine is a sublingually administered, atypical antipsychotic for treatment of schizophrenia and acute mania associated with bipolar disorder. Asenapine also belongs to the dibenzo-oxepino pyrrole class. It is also for severe post-traumatic stress disorder nightmares in soldiers as an off-label use. FDA approved on August 13, 2009.

Properties:

solid

Avg. mass: 285.77 Da

View FDA drug label

DrugBank indication

Used for treatment in psychosis, schizophrenia and schizoaffective disorders, manic disorders, and bipolar disorders as monotherapy or in combination.

Also known as(133)

Asenapina

Asenapine

5-HT-2

5-HT-2A

HTR2

Serotonin receptor 2A

Dopamine D2 receptor

5-HT-1A

Dosage forms(13)

Tablet (Sublingual) — 10 mg/1

Tablet (Sublingual) — 10 mg

Tablet (Sublingual) — 2.5 mg/1

Tablet (Sublingual) — 5 mg/1

Tablet (Sublingual) — 5 mg

Film, extended release (Transdermal) — 3.8 mg/1d

Film, extended release (Transdermal) — 5.7 mg/1d

Film, extended release (Transdermal) — 7.6 mg/1d

Molecular properties(18)

Drug interactions(1737)

Known interactions with other medications. Always consult a healthcare professional.

Fluvoxamine

Unknown severity

DB00176

The serum concentration of Asenapine can be increased when it is combined with Fluvoxamine.

Check this interaction

Deferasirox

Unknown severity

DB01609

The serum concentration of Asenapine can be increased when it is combined with Deferasirox.

Check this interaction

Peginterferon alfa-2b

Unknown severity

DB00022

The serum concentration of Asenapine can be increased when it is combined with Peginterferon alfa-2b.

Check this interaction

Leflunomide

Unknown severity

DB01097

The serum concentration of Asenapine can be decreased when it is combined with Leflunomide.

Check this interaction

Teriflunomide

Unknown severity

DB08880

The serum concentration of Asenapine can be decreased when it is combined with Teriflunomide.

Check this interaction

Valsartan

Moderate

DB00177

Asenapine may decrease the antihypertensive activities of Valsartan.

Check this interaction

Ramipril

Moderate

DB00178

Asenapine may decrease the antihypertensive activities of Ramipril.

Check this interaction

Remikiren

Moderate

DB00212

Asenapine may decrease the antihypertensive activities of Remikiren.

Check this interaction

Torasemide

Moderate

DB00214

Asenapine may decrease the antihypertensive activities of Torasemide.

Check this interaction

Guanadrel

Moderate

DB00226

Asenapine may decrease the antihypertensive activities of Guanadrel.

Check this interaction

Olmesartan

Moderate

DB00275

Asenapine may decrease the antihypertensive activities of Olmesartan.

Check this interaction

Chlorthalidone

Moderate

DB00310

Asenapine may decrease the antihypertensive activities of Chlorthalidone.

Check this interaction

Nitroprusside

Moderate

DB00325

Asenapine may decrease the antihypertensive activities of Nitroprusside.

Check this interaction

Minoxidil

Moderate

DB00350

Asenapine may decrease the antihypertensive activities of Minoxidil.

Check this interaction

Bendroflumethiazide

Moderate

DB00436

Asenapine may decrease the antihypertensive activities of Bendroflumethiazide.

Check this interaction

Fosinopril

Moderate

DB00492

Asenapine may decrease the antihypertensive activities of Fosinopril.

Check this interaction

Trandolapril

Moderate

DB00519

Asenapine may decrease the antihypertensive activities of Trandolapril.

Check this interaction

Metolazone

Moderate

DB00524

Asenapine may decrease the antihypertensive activities of Metolazone.

Check this interaction

Benazepril

Moderate

DB00542

Asenapine may decrease the antihypertensive activities of Benazepril.

Check this interaction

Cyclothiazide

Moderate

DB00606

Asenapine may decrease the antihypertensive activities of Cyclothiazide.

Check this interaction

Candoxatril

Moderate

DB00616

Asenapine may decrease the antihypertensive activities of Candoxatril.

Check this interaction

Mecamylamine

Moderate

DB00657

Asenapine may decrease the antihypertensive activities of Mecamylamine.

Check this interaction

Lisinopril

Moderate

DB00722

Asenapine may decrease the antihypertensive activities of Lisinopril.

Check this interaction

Nitroglycerin

Moderate

DB00727

Asenapine may decrease the antihypertensive activities of Nitroglycerin.

Check this interaction

Hydroflumethiazide

Moderate

DB00774

Asenapine may decrease the antihypertensive activities of Hydroflumethiazide.

Check this interaction

Cryptenamine

Moderate

DB00785

Asenapine may decrease the antihypertensive activities of Cryptenamine.

Check this interaction

Perindopril

Moderate

DB00790

Asenapine may decrease the antihypertensive activities of Perindopril.

Check this interaction

Candesartan cilexetil

Moderate

DB00796

Asenapine may decrease the antihypertensive activities of Candesartan cilexetil.

Check this interaction

Eprosartan

Moderate

DB00876

Asenapine may decrease the antihypertensive activities of Eprosartan.

Check this interaction

Chlorothiazide

Moderate

DB00880

Asenapine may decrease the antihypertensive activities of Chlorothiazide.

Check this interaction

Quinapril

Moderate

DB00881

Asenapine may decrease the antihypertensive activities of Quinapril.

Check this interaction

Telmisartan

Moderate

DB00966

Asenapine may decrease the antihypertensive activities of Telmisartan.

Check this interaction

Trichlormethiazide

Moderate

DB01021

Asenapine may decrease the antihypertensive activities of Trichlormethiazide.

Check this interaction

Deserpidine

Moderate

DB01089

Asenapine may decrease the antihypertensive activities of Deserpidine.

Check this interaction

Pentolinium

Moderate

DB01090

Asenapine may decrease the antihypertensive activities of Pentolinium.

Check this interaction

Trimethaphan

Moderate

DB01116

Asenapine may decrease the antihypertensive activities of Trimethaphan.

Check this interaction

Diazoxide

Moderate

DB01119

The metabolism of Asenapine can be decreased when combined with Diazoxide.

Check this interaction

Epoprostenol

Moderate

DB01240

Asenapine may decrease the antihypertensive activities of Epoprostenol.

Check this interaction

Polythiazide

Moderate

DB01324

Asenapine may decrease the antihypertensive activities of Polythiazide.

Check this interaction

Cilazapril

Moderate

DB01340

Asenapine may decrease the antihypertensive activities of Cilazapril.

Check this interaction

Saprisartan

Moderate

DB01347

Asenapine may decrease the antihypertensive activities of Saprisartan.

Check this interaction

Spirapril

Moderate

DB01348

Asenapine may decrease the antihypertensive activities of Spirapril.

Check this interaction

Tienilic acid

Moderate

DB04831

Asenapine may decrease the antihypertensive activities of Tienilic acid.

Check this interaction

Diethylnorspermine

Moderate

DB06445

Asenapine may decrease the antihypertensive activities of Diethylnorspermine.

Check this interaction

Temocapril

Moderate

DB08836

Asenapine may decrease the antihypertensive activities of Temocapril.

Check this interaction

Nicorandil

Moderate

DB09220

Asenapine may decrease the antihypertensive activities of Nicorandil.

Check this interaction

Rauwolfia serpentina root

Moderate

DB09363

Asenapine may decrease the antihypertensive activities of Rauwolfia serpentina root.

Check this interaction

Enalaprilat

Moderate

DB09477

Asenapine may decrease the antihypertensive activities of Enalaprilat.

Check this interaction

Angiotensin 1-7

Moderate

DB11720

Asenapine may decrease the antihypertensive activities of Angiotensin 1-7.

Check this interaction

Imidapril

Moderate

DB11783

Asenapine may decrease the antihypertensive activities of Imidapril.

Check this interaction

Showing 50 of 1737 interactions

Food & lifestyle interactions

Advice

Take separate from meals. Do not have food or water for 10 minutes after administration.

How it works

Mechanism of action

Asenapine is an atypical antipsychotic multireceptor neuroleptic drug which shows strong 5HT2A (serotonin) and D2 (dopamine) receptor antagonism, which has been shown to enhance dopamine (DA) and acetylcholine (Ach) efflux in rat brains. Asenapine may improve cognitive function and negative symptoms in patients with schizophrenia.

Pharmacodynamics

Asenapine is a serotonin, dopamine, noradrenaline, and histamine antagonist in which asenapine possess more potent activity with serotonin receptors than dopamine. Sedation in patients is associated with asenapine's antagonist activity at histamine receptors. Its lower incidence of extrapyramidal effects are associated with the upregulation of D1 receptors. This upregulation occurs due to asenapine's dose-dependent effects on glutamate transmission in the brain. It does not have any significant activity with muscarinic, cholinergic receptors therefore symptoms associated with anticholinergic drug activity like dry mouth or constipation are not expected to be observed. Asenapine has a higher affinity for all aforementioned receptors compared to first-generation and second-generation antipsychotics except for 5-HT1A and 5-HT1B receptors.

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Absorption

Cmax, single 5 mg dose = 4 ng/mL (within 1 hour);
Bioavailability, sublingual administration = 35%;
Bioavailability, oral administration (swallowed) = <2%;
Time to steady state, 5 mg = 3 days;
Peak plasma concentration occurs within 0.5 to 1.5 hours. Doubling dose of asenapine results in 1.7-fold increase in maximum concentration and exposure. Drinking water within 2-5 minutes post administration of asenapine results in a decrease in exposure.

Half-life

24 hours (range of 13.4 - 39.2 hours)

Protein binding

95% protein bound

Volume of distribution

20-25 L/kg

Metabolism

Asenapine is oxidized via CYP1A2 and undergoes direct glucuronidation via UGT1A4. Oxidation via CYP1A2 is asenapine's primary mode of metabolism.

Route of elimination

Urine (50%) and feces (50%)

Drug targets(20)

Proteins and enzymes this drug interacts with in the body

5-hydroxytryptamine receptor 2A

BE0000451

HTR2A

antagonist

Specific function1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding

Cellular location

Cell membrane

General function & pharmacology

G-protein coupled receptor for 5-hydroxytryptamine (serotonin) .
PMID:1330647 PMID:18703043 PMID:19057895 PMID:21645528 PMID:22300836 PMID:35084960 PMID:38552625

Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD) .
PMID:28129538 PMID:35084960
Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors .
PMID:28129538 PMID:35084960
HTR2A is coupled to G(q)/G(11) G alpha proteins and activates phospholipase C-beta, releasing diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) second messengers that modulate the activity of phosphatidylinositol 3-kinase and promote the release of Ca(2+) ions from intracellular stores, respectively .
PMID:18703043 PMID:28129538 PMID:35084960

Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways .
PMID:28129538 PMID:35084960
Affects neural activity, perception, cognition and mood .
PMID:18297054
Plays a role in the regulation of behavior, including responses to anxiogenic situations and psychoactive substances. Plays a role in intestinal smooth muscle contraction, and may play a role in arterial vasoconstriction (By similarity)

D(2) dopamine receptor

BE0000756

DRD2

antagonist

Specific functiondopamine binding

Cellular location

Cell membrane

General function & pharmacology

Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase .
PMID:21645528
Positively regulates postnatal regression of retinal hyaloid vessels via suppression of VEGFR2/KDR activity, downstream of OPN5 (By similarity)

5-hydroxytryptamine receptor 1A

BE0000291

HTR1A

antagonist

Specific functionG protein-coupled serotonin receptor activity

Cellular location

Cell membrane

General function & pharmacology

G-protein coupled receptor for 5-hydroxytryptamine (serotonin) .
PMID:22957663 PMID:3138543 PMID:33762731 PMID:37935376 PMID:37935377 PMID:8138923 PMID:8393041

Also functions as a receptor for various drugs and psychoactive substances .
PMID:22957663 PMID:3138543 PMID:33762731 PMID:38552625 PMID:8138923 PMID:8393041

Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase .
PMID:22957663 PMID:3138543 PMID:33762731 PMID:8138923 PMID:8393041

HTR1A is coupled to G(i)/G(o) G alpha proteins and mediates inhibitory neurotransmission: signaling inhibits adenylate cyclase activity and activates a phosphatidylinositol-calcium second messenger system that regulates the release of Ca(2+) ions from intracellular stores .
PMID:33762731 PMID:35610220
Beta-arrestin family members regulate signaling by mediating both receptor desensitization and resensitization processes .
PMID:18476671 PMID:20363322 PMID:20945968

Plays a role in the regulation of 5-hydroxytryptamine release and in the regulation of dopamine and 5-hydroxytryptamine metabolism .
PMID:18476671 PMID:20363322 PMID:20945968

Plays a role in the regulation of dopamine and 5-hydroxytryptamine levels in the brain, and thereby affects neural activity, mood and behavior .
PMID:18476671 PMID:20363322 PMID:20945968

Plays a role in the response to anxiogenic stimuli PMID:18476671 PMID:20363322 PMID:20945968

5-hydroxytryptamine receptor 1B

BE0000797

HTR1B

antagonist

Specific functionG protein-coupled serotonin receptor activity

Cellular location

Cell membrane

General function & pharmacology

G-protein coupled receptor for 5-hydroxytryptamine (serotonin) .
PMID:10452531 PMID:1315531 PMID:1328844 PMID:1348246 PMID:1351684 PMID:1559993 PMID:1565658 PMID:1610347 PMID:23519210 PMID:23519215 PMID:29925951 PMID:8218242

Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances, such as lysergic acid diethylamide (LSD) .
PMID:23519210 PMID:23519215 PMID:29925951

Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase .
PMID:10452531 PMID:1315531 PMID:1328844 PMID:1348246 PMID:1351684 PMID:1559993 PMID:1565658 PMID:1610347 PMID:23519210 PMID:23519215 PMID:29925951 PMID:8218242

HTR1B is coupled to G(i)/G(o) G alpha proteins and mediates inhibitory neurotransmission by inhibiting adenylate cyclase activity .
PMID:29925951 PMID:35610220
Arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways .
PMID:29925951
Regulates the release of 5-hydroxytryptamine, dopamine and acetylcholine in the brain, and thereby affects neural activity, nociceptive processing, pain perception, mood and behavior .
PMID:18476671 PMID:20945968
Besides, plays a role in vasoconstriction of cerebral arteries PMID:15853772

5-hydroxytryptamine receptor 2B

BE0000393

HTR2B

antagonist

Specific functionG protein-coupled serotonin receptor activity

Cellular location

Cell membrane

General function & pharmacology

G-protein coupled receptor for 5-hydroxytryptamine (serotonin) .
PMID:18703043 PMID:23519210 PMID:7926008 PMID:8078486 PMID:8143856 PMID:8882600

Also functions as a receptor for various ergot alkaloid derivatives and psychoactive substances .
PMID:12970106 PMID:18703043 PMID:23519210 PMID:23519215 PMID:24357322 PMID:28129538 PMID:30127358 PMID:36087581 PMID:7926008 PMID:8078486 PMID:8143856

Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors .
PMID:23519215 PMID:28129538 PMID:8078486 PMID:8143856 PMID:8882600

HTR2B is coupled to G(q)/G(11) G alpha proteins and activates phospholipase C-beta, releasing diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) second messengers that modulate the activity of phosphatidylinositol 3-kinase and promote the release of Ca(2+) ions from intracellular stores, respectively .
PMID:18703043 PMID:23519215 PMID:28129538 PMID:30127358 PMID:36087581 PMID:8078486 PMID:8143856 PMID:8882600

Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways .
PMID:23519215 PMID:28129538 PMID:30127358 PMID:36087581

Plays a role in the regulation of dopamine and 5-hydroxytryptamine release, 5-hydroxytryptamine uptake and in the regulation of extracellular dopamine and 5-hydroxytryptamine levels, and thereby affects neural activity. May play a role in the perception of pain (By similarity). Plays a role in the regulation of behavior, including impulsive behavior .
PMID:21179162
Required for normal proliferation of embryonic cardiac myocytes and normal heart development (By similarity).

Protects cardiomyocytes against apoptosis (By similarity). Plays a role in the adaptation of pulmonary arteries to chronic hypoxia (By similarity). Plays a role in vasoconstriction (By similarity).

Required for normal osteoblast function and proliferation, and for maintaining normal bone density (By similarity). Required for normal proliferation of the interstitial cells of Cajal in the intestine (By similarity)

Metabolizing enzymes(4)

Enzymes involved in drug metabolism — important for understanding drug interactions

Enzyme activity key

substrate

inhibitor

inducer

UGT1A4UDP-glucuronosyltransferase 1A4

substrate

CYP1A2Cytochrome P450 1A2

substrate

CYP2D6Cytochrome P450 2D6

substrate

inhibitor

CYP3A4Cytochrome P450 3A4

substrate

Carriers(2)

Proteins that carry this drug through the body

Albumin

BE0000530

ALB

binder

Specific functionantioxidant activity

Cellular location

Secreted

General function & pharmacology

Binds water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs (Probable). Its main function is the regulation of the colloidal osmotic pressure of blood (Probable). Major zinc transporter in plasma, typically binds about 80% of all plasma zinc .
PMID:19021548
Major calcium and magnesium transporter in plasma, binds approximately 45% of circulating calcium and magnesium in plasma (By similarity).

Potentially has more than two calcium-binding sites and might additionally bind calcium in a non-specific manner (By similarity). The shared binding site between zinc and calcium at residue Asp-273 suggests a crosstalk between zinc and calcium transport in the blood (By similarity). The rank order of affinity is zinc > calcium > magnesium (By similarity).

Binds to the bacterial siderophore enterobactin and inhibits enterobactin-mediated iron uptake of E.coli from ferric transferrin, and may thereby limit the utilization of iron and growth of enteric bacteria such as E.coli .
PMID:6234017
Does not prevent iron uptake by the bacterial siderophore aerobactin PMID:6234017

Alpha-1-acid glycoprotein 2

BE0004879

ORM2

binder

Cellular location

Secreted

General function & pharmacology

Functions as a transport protein in the blood stream. Binds various hydrophobic ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability.

Appears to function in modulating the activity of the immune system during the acute-phase reaction

Scientific references(4)

Huang M., Li Z., Dai J., Shahid M., Wong E.H., Meltzer H.Y.

Asenapine increases dopamine, norepinephrine, and acetylcholine efflux in the rat medial prefrontal cortex and hippocampus.

Neuropsychopharmacology

2008 Nov33(12):2934-45. doi: 10.1038/npp.2008.20. Epub 2008 Apr 16

PMID: 18418367 DOI: 10.1038/npp.2008.20

Shahid M., Walker G.B., Zorn S.H., Wong E.H.

Asenapine: a novel psychopharmacologic agent with a unique human receptor signature.

Journal Psychopharmacology

2009 Jan23(1):65-73. doi: 10.1177/0269881107082944. Epub 2008 Feb 28

PMID: 18308814 DOI: 10.1177/0269881107082944

Franberg O., Wiker C., Marcus M.M., Konradsson A., Jardemark K., Schilstrom B., Shahid M., Wong E.H., Svensson T.H.

Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia.

Psychopharmacology

2008196(3):417-429. doi: 10.1007/s00213-007-0973-y

PMID: 17940749 DOI: 10.1007/s00213-007-0973-y

Fagiolini A., Forgione R.N., Morana B., Maccari M., Goracci A., Bossini L., Pellegrini F., Cuomo A., Casamassima F.

Asenapine for the treatment of manic and mixed episodes associated with bipolar I disorder: from clinical research to clinical practice.

Expert Opinion on Pharmacotherapy

2013 Mar14(4):489-504. doi: 10.1517/14656566.2013.765859. Epub 2013 Jan 29

PMID: 23356509 DOI: 10.1517/14656566.2013.765859

ATC classification(1 code)

ATC N05AH05

Affected organisms(1)

Humans and other mammals

Salt forms(1)

Asenapine maleate(DBSALT000010)

External resources(2)

RxList Drugs.com

Commercial products(43)

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

Linked compound data from DrugBank Open Data (CC BY-NC 4.0)

Asenapine

DB06216

CAS number

65576-45-6

UNII (FDA)

JKZ19V908O

InChI Key (molecular fingerprint)

VSWBSWWIRNCQIJ-UHFFFAOYSA-N

Additional database identifiers

Drugs Product Database (DPD)

21015

ChEBI

71255

PubChem Compound

11954293

PubChem Substance

175427062

KEGG Drug

D02995

ChemSpider

8079624

Wikipedia

Asenapine

ChEMBL

CHEMBL3187365

ZINC

ZINC000000002299

RxCUI

784649

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5293

GenAtlas

HTR2A

GeneCards

HTR2A

GenBank Gene Database

S42168

GenBank Protein Database

36431

IUPHAR

Guide to Pharmacology

UniProtKB

P28223

UniProt Accession

5HT2A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:3023

GenAtlas

DRD2

GeneCards

DRD2

GenBank Gene Database

M30625

GenBank Protein Database

181432

IUPHAR

215

Guide to Pharmacology

215

UniProtKB

P14416

UniProt Accession

DRD2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5286

GenAtlas

HTR1A

GeneCards

HTR1A

GenBank Gene Database

M28269

GenBank Protein Database

189928

IUPHAR

Guide to Pharmacology

UniProtKB

P08908

UniProt Accession

5HT1A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5287

GenAtlas

HTR1B

GeneCards

HTR1B

GenBank Gene Database

D10995

GenBank Protein Database

219679

IUPHAR

Guide to Pharmacology

UniProtKB

P28222

UniProt Accession

5HT1B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5294

GenAtlas

HTR2B

GeneCards

HTR2B

GenBank Gene Database

X77307

GenBank Protein Database

475198

IUPHAR

Guide to Pharmacology

UniProtKB

P41595

UniProt Accession

5HT2B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5295

GenAtlas

HTR2C

GeneCards

HTR2C

GenBank Gene Database

M81778

GenBank Protein Database

338028

IUPHAR

Guide to Pharmacology

UniProtKB

P28335

UniProt Accession

5HT2C_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5300

GeneCards

HTR5A

Guide to Pharmacology

UniProtKB

P47898

UniProt Accession

5HT5A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5301

GenAtlas

HTR6

GeneCards

HTR6

GenBank Gene Database

L41147

GenBank Protein Database

1162924

IUPHAR

Guide to Pharmacology

UniProtKB

P50406

UniProt Accession

5HT6R_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5302

GenAtlas

HTR7

GeneCards

HTR7

GenBank Gene Database

U68487

GenBank Protein Database

1857143

IUPHAR

Guide to Pharmacology

UniProtKB

P34969

UniProt Accession

5HT7R_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:3024

GenAtlas

DRD3

GeneCards

DRD3

GenBank Gene Database

U32499

GenBank Protein Database

927342

IUPHAR

216

Guide to Pharmacology

216

UniProtKB

P35462

UniProt Accession

DRD3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:3025

GenAtlas

DRD4

GeneCards

DRD4

GenBank Gene Database

L12398

GenBank Protein Database

291946

IUPHAR

217

Guide to Pharmacology

217

UniProtKB

P21917

UniProt Accession

DRD4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:3020

GenAtlas

DRD1

GeneCards

DRD1

GenBank Gene Database

X55760

GenBank Protein Database

30397

IUPHAR

214

Guide to Pharmacology

214

UniProtKB

P21728

UniProt Accession

DRD1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:277

GenAtlas

ADRA1A

GeneCards

ADRA1A

GenBank Gene Database

D25235

GenBank Protein Database

433201

IUPHAR

Guide to Pharmacology

UniProtKB

P35348

UniProt Accession

ADA1A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:281

GenAtlas

ADRA2A

GeneCards

ADRA2A

GenBank Gene Database

M23533

GenBank Protein Database

178196

IUPHAR

Guide to Pharmacology

UniProtKB

P08913

UniProt Accession

ADA2A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:282

GenAtlas

ADRA2B

GeneCards

ADRA2B

GenBank Gene Database

M34041

GenBank Protein Database

178198

IUPHAR

Guide to Pharmacology

UniProtKB

P18089

UniProt Accession

ADA2B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:283

GenAtlas

ADRA2C

GeneCards

ADRA2C

GenBank Gene Database

J03853

GenBank Protein Database

178194

IUPHAR

Guide to Pharmacology

UniProtKB

P18825

UniProt Accession

ADA2C_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5182

GenAtlas

HRH1

GeneCards

HRH1

GenBank Gene Database

Z34897

GenBank Protein Database

510296

IUPHAR

262

Guide to Pharmacology

262

UniProtKB

P35367

UniProt Accession

HRH1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5183

GenAtlas

HRH2

GeneCards

HRH2

GenBank Gene Database

M64799

GenBank Protein Database

184088

IUPHAR

263

Guide to Pharmacology

263

UniProtKB

P25021

UniProt Accession

HRH2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:285

GenAtlas

ADRB1

GeneCards

ADRB1

GenBank Gene Database

J03019

GenBank Protein Database

178200

IUPHAR

Guide to Pharmacology

UniProtKB

P08588

UniProt Accession

ADRB1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:286

GenAtlas

ADRB2

GeneCards

ADRB2

GenBank Gene Database

Y00106

GenBank Protein Database

29371

IUPHAR

Guide to Pharmacology

UniProtKB

P07550

UniProt Accession

ADRB2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:12536

GeneCards

UGT1A4

GenBank Gene Database

M57951

GenBank Protein Database

184475

UniProtKB

P22310

UniProt Accession

UD14_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2596

GenAtlas

CYP1A2

GeneCards

CYP1A2

GenBank Gene Database

Z00036

Guide to Pharmacology

1319

UniProtKB

P05177

UniProt Accession

CP1A2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2625

GenAtlas

CYP2D6

GeneCards

CYP2D6

GenBank Gene Database

M20403

GenBank Protein Database

181350

Guide to Pharmacology

1329

UniProtKB

P10635

UniProt Accession

CP2D6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2637

GenAtlas

CYP3A4

GeneCards

CYP3A4

GenBank Gene Database

M18907

Guide to Pharmacology

1337

UniProtKB

P08684

UniProt Accession

CP3A4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:399

GenAtlas

ALB

GeneCards

ALB

GenBank Gene Database

V00494

GenBank Protein Database

28590

UniProtKB

P02768

UniProt Accession

ALBU_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:8498

GenAtlas

ORM1

GeneCards

ORM1

GenBank Gene Database

X02544

GenBank Protein Database

757907

UniProtKB

P02763

UniProt Accession

A1AG1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:8499

GeneCards

ORM2

GenBank Gene Database

BC015964

GenBank Protein Database

16359000

UniProtKB

P19652

UniProt Accession

A1AG2_HUMAN

Patent information

8 active patents, 1 expired

11813364

United States

Approved 14 Nov 2023 · Expires 22 Sept 2033

7y 5m

9687474

United States

Approved 27 Jun 2017 · Expires 25 Jul 2033

7y 3m

10022445

United States

Approved 17 Jul 2018 · Expires 25 Jul 2033

7y 3m

10583121

United States

Approved 10 Mar 2020 · Expires 25 Jul 2033

7y 3m

10814002

United States

Approved 27 Oct 2020 · Expires 25 Jul 2033

7y 3m

The earliest active patent expires October 2026. Generic versions may become available after this date.

Source: DrugBank · CC BY-NC 4.0. Patent data sourced from national patent offices. Expiry dates may not reflect extensions, regulatory exclusivity periods, or legal challenges.

DrugBank citations

If you use DrugBank data in your research, please cite the following publications:

Knox C., Wilson M., Klinger C.M., et al

DrugBank 6.

0: the DrugBank Knowledgebase for 2024

Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275

PMID: 37953279

Wishart D.S., Feunang Y.D., Guo A.C., et al

DrugBank 5.

0: a major update to the DrugBank database for 2018

Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082

PMID: 29126136

Show earlier publications

Law V., Knox C., Djoumbou Y., et al

DrugBank 4.

0: shedding new light on drug metabolism

Nucleic Acids Res. 2014 Jan 142(1):D1091-7

PMID: 24203711

Knox C., Law V., Jewison T., et al

DrugBank 3.

0: a comprehensive resource for 'omics' research on drugs

Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41

PMID: 21059682

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a knowledgebase for drugs, drug actions and drug targets.

Nucleic Acids Research

2008 Jan36(Database issue):D901-6

PMID: 18048412

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a comprehensive resource for in silico drug discovery and exploration.

Nucleic Acids Research

2006 Jan 134(Database issue):D668-72

PMID: 16381955

Source: go.drugbank.comCC BY-NC 4.0

Updated 26 days ago(8 Mar 2026)

Back to medicines

Asenapine 5.7mg/24hours transdermal patches

Safety monitoring data

Yellow Card reports

EudraVigilance

British National Formulary

NICE clinical guidance(1)

Pharmacy stock checkers

Supply & product information

NHS UK identifiers

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Volume of distribution

Metabolism

Elimination

Clinical essentials

Pharmacology

Deep science
26

Chemical identifiers

Asenapine

Additional database identifiers

Patent information

DrugBank citations

Asenapine 5.7mg/24hours transdermal patches

Safety & regulatory

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

Guidance (NICE / BNF)

British National Formulary

NICE clinical guidance(1)

Availability, stocks & shortages

Pharmacy stock checkers

Supply & product information

Professional identifiers

NHS UK identifiers

Clinical trials

DrugBank data

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Volume of distribution

Metabolism

Elimination

Clinical essentials

Pharmacology

Deep science26

Chemical identifiers

Asenapine

Additional database identifiers

Patent information

DrugBank citations

Deep science
26